Clinical trial Recruiting at 3 sites Observational Women only

Monitoring pregnancy outcomes for patients using Epidiolex during pregnancy

Official title: Observational Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy to Assess the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant

Run by Jazz Pharmaceuticals · NCT06113237 · Data updated 2026-11-12

This study looks at how using Epidiolex during pregnancy affects the health of mothers and their babies to see what outcomes they experience.

Quick facts

Study typeObservational
SexWomen only
Enrollment50 (estimated)
SponsorJazz Pharmaceuticals
Industry-sponsored
Locations3 sites (Morgantown, West Virginia and 2 other locations)
StatusRecruiting
StartedAugust 5, 2025
Main results expectedAugust 31, 2033
Study endsAugust 31, 2033
Registry record updatedOctober 2, 2026
Trial IDNCT06113237 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are pregnant women who have been exposed to Epidiolex or Epidyolex during their pregnancy.

Probably not a fit

Patients who have used non-regulatory approved products containing CBD without exposure to Epidiolex will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the health outcomes related to pregnancy in women who have been exposed to Epidiolex or Epidyolex. It will track maternal complications, pregnancy complications, and birth outcomes, as well as monitor the health of infants up to 12 months of age. Participants must have received at least one dose of Epidiolex during the specified time frame. The study will gather data to better understand the implications of Epidiolex exposure during pregnancy.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the safety and effects of Epidiolex use during pregnancy, potentially guiding treatment decisions for expectant mothers.

How similar studies have gone: While there may be limited data on similar studies, this approach is relatively novel in the context of monitoring pregnancy outcomes specifically related to Epidiolex exposure.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients with exposure to at least 1 dose of Epidiolex/Epidyolex during the 13 days prior to their LMP or at any time during pregnancy.
2. Verbal or written informed consent to participate

Exclusion criteria:

1\) Patients exposed to a non-regulatory approved product containing Cannabidiol (CBD) during pregnancy who do not also have exposure to Epidiolex during the 13 days prior to their LMP or during the pregnancy.

Where it's running

  • United Biosource LLC
    Morgantown, West Virginia, United States
    Recruiting
  • Vivantes Humboldt-Klinikum Klinik für Neurologie
    Berlin, Germany
    Recruiting
  • JZP047-102 Research Summary for UK IRAS application
    Bologna, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.